

CURRICULUM VITAE

Guan Chen PhD, MD

Professor

Department of Pharmacology and Toxicology

OFFICE ADDRESS:

8701 Watertown Plank Road

Milwaukee, WI 53226

Phone: +1 (414) 4568636

Email: gchen@mcw.edu

EDUCATION:

01/1982 - Present MD, Bengbu Medical College, Anhui, P.R. China

1982 MD, Bengbu Medical College, Anhui, P.R. China

01/1985 - Present MS, Sun Yat-Sen University, GuangZhou, P.R. China

1985 MS, Sun Yat-Sen University, GuangZhou, P.R. China

01/1990 - Present PhD, University of Heidelberg, Heidelberg, Germany

1990 PhD, University of Heidelberg, Heidelberg, Germany

01/1995 - Present Post Doctorate, Dana-Farber Cancer Institute, Harvard Medical School, Boston

1995 Post Doctorate, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

FACULTY APPOINTMENTS:

01/1986 - 12/1987 Research Associate, Cancer Institute, Sun Yat-Sen University, GuangZhou, P.R. China

1986 - 1987 Research Associate, Cancer Institute, Sun Yat-Sen University, GuangZhou, P.R. China

01/1988 - Present Lecturer, Cancer Institute, Sun Yat-Sen University, GuangZhou, P.R. China

01/1988 - 12/1992 Guest Scientist, Inst. of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, Germany

1988 Lecturer, Cancer Institute, Sun Yat-Sen University, GuangZhou, P.R. China

1988 - 1992 Guest Scientist, Inst. of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, Germany

01/1992 - 12/1995 Postdoctoral Research Fellow, Dana-Farber Institute, Harvard Medical School, MA, Division of Cancer Pharmacology, Boston

1992 - 1995 Postdoctoral Research Fellow, Dana-Farber Institute, Division of Cancer Pharmacology, Harvard Medical School, Boston, MA

01/1995 - 12/2000 Assistant Professor, Department of Molecular Biology, Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, OH

1995 - 2000 Assistant Professor, Department of Molecular Biology, Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, OH

09/01/2000 - Present Associate Professor, Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153

09/2000 - Present Associate Professor, Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153

07/01/2003 - Present Associate Professor, Department of Radiation Oncology, Loyola University of Chicago, Maywood, IL 60153

07/2003 - Present Associate Professor, Department of Radiation Oncology, Loyola University of Chicago, Maywood, IL 60153

02/01/2004 - Present Associate Professor, Department of Pharmacology and Experimental Therapeutics, Loyola University of Chicago, Maywood, IL 60153

02/2004 - Present Associate Professor, Department of Pharmacology and Experimental Therapeutics, Loyola

University of Chicago, Maywood, IL 60153
03/01/2006 - Present Professor, Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226
03/2006 - Present Professor, Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:

09/01/2000 - Present Member of Molecular Biology Program, Graduate School, Loyola University of Chicago, Maywood, IL 60153
09/01/2000 - Present Member of Molecular and Cellular Biochemistry Program, Graduate School, Loyola University of Chicago, Maywood, IL 60153
09/2000 - Present Member of Molecular and Cellular Biochemistry Program, Graduate School, Loyola University of Chicago, Maywood, IL 60153
09/2000 - Present Member of Molecular Biology Program, Graduate School, Loyola University of Chicago, Maywood, IL 60153

AWARDS AND HONORS:

1988 - 1992 Guest Scientist Scholarship, German Cancer Research Center (DKFZ) in Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, Germany
1988 - 1992 Guest Scientist Scholarship, German Cancer Research Center (DKFZ) in Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, Germany
1989 - Present Gerhard-Domagk Award
1989 Gerhard-Domagk Award

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

1997 - Present New York Academy of Sciences (Active Member)
1997 - Present New York Academy of Sciences (Active Member)
2012 - Present Federation of American Societies for Experimental Biology (Member)
2012 - Present American Society for Pharmacology and Experimental Therapeutics (Member)
2012 - Present American Society for Biochemistry and Molecular Biology (Member)
2012 - Present American Association for Cancer Research (Active Member)
American Society for Pharmacology and Experimental Therapeutics (Member)
American Association for Cancer Research (Active Member)
Federation of American Societies for Experimental Biology (Member)
American Society for Biochemistry and Molecular Biology (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorship

2001 - Present Frontier in Biosciences
2001 - Present Frontier in Biosciences
2006 - 2010 International Journal of Cancer Research
2006 - 2010 International Journal of Cancer Research
2010 - Present American Journal of Cancer Research
2010 - Present American Journal of Cancer Research

Journal Review

2012 - Present Cancer Res., Blood, Int. J. Cancer, Oncogene, BBRC, Carcinogenesis, FASEB J., BBA, Int J Biol Sci
Cancer Res., Blood, Int. J. Cancer, Oncogene, BBRC, Carcinogenesis, FASEB J., BBA, Int J Biol Sci

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

01/2000 - 12/2006 Member, Recruiting Committee for Cancer Center, Department of Radiation Oncology; Department of Urology, and Program of Hematology, and Skin Cancer Program, Loyola University
01/2000 - 12/2002 Co-Chair, Research Safety Committee, Hines VA Medical Center, Loyola University
2000 - 2006 Member, Recruiting Committee for Cancer Center, Department of Radiation Oncology; Department of Urology, and Program of Hematology, and Skin Cancer Program, Loyola University
2000 - 2002 Co-Chair, Research Safety Committee, Hines VA Medical Center, Loyola University
01/2002 - Present Member, Graduate admission committee, Molecular Biology Program, Loyola University

of Chicago
 01/2002 - 12/2004 Member, Research Safety Committee, Hines VA Medical Center
 2002 - Present Member, Graduate admission committee, Molecular Biology Program, Loyola University of Chicago
 2002 - 2004 Member, Research Safety Committee, Hines VA Medical Center
 01/2003 - 12/2006 Member, Faculty recruiting committee, Department of Pharmacology, Loyola University
 2003 - 2006 Member, Faculty recruiting committee, Department of Pharmacology, Loyola University
 01/2004 - Present Member, Research & Development Committee, Research Services, Hines VA Medical Center
 01/2004 - 12/2006 Member, Hematology/Oncology Grand Review Panel, Cancer Center, Loyola University of Chicago
 01/2004 - 12/2006 Member, Core Curriculum Oversight Committee, Loyola Graduate School, Loyola University of Chicago
 01/2004 - Present Member, Graduate admission committee, Department of Pharmacology, Loyola
 2004 - 2006 Member, Core Curriculum Oversight Committee, Loyola Graduate School, Loyola University of Chicago
 2004 - Present Member, Research & Development Committee, Research Services, Hines VA Medical Center
 2004 - 2006 Member, Hematology/Oncology Grand Review Panel, Cancer Center, Loyola University of Chicago
 2004 - Present Member, Graduate admission committee, Department of Pharmacology, Loyola
 01/2006 - Present Member, PhD candidate Recruiting, Graduate School, Medical College of Wisconsin
 01/2006 - Present Member, Blood Institute of Wisconsin Recruiting, Medical College of Wisconsin
 01/2006 - Present Member, Department of Biochemistry recruiting Committee, Medical College of Wisconsin
 01/2006 - Present Member, Department of Medicine/Division of Endocrinology recruiting, Medical College of Wisconsin
 01/2006 - Present Member, Cancer Center Open House, Medical College of Wisconsin
 01/2006 - Present Member, Department of Pharmacology recruiting Committee, Medical College of Wisconsin
 2006 - Present Member, Department of Medicine/Division of Endocrinology recruiting, Medical College of Wisconsin
 2006 - Present Member, Blood Institute of Wisconsin Recruiting, Medical College of Wisconsin
 2006 - Present Member, Cancer Center Open House, Medical College of Wisconsin
 2006 - Present Member, Department of Pharmacology recruiting Committee, Medical College of Wisconsin
 2006 - Present Member, PhD candidate Recruiting, Graduate School, Medical College of Wisconsin
 2006 - Present Member, Department of Biochemistry recruiting Committee, Medical College of Wisconsin
 01/2007 - 12/2008 Member, Curriculum and Programs Committee, Graduate School, Medical College of Wisconsin
 01/2007 - Present Recruiting Director, Department of Pharmacology and Toxicology, Medical College of Wisconsin
 2007 - 2008 Member, Curriculum and Programs Committee, Graduate School, Medical College of Wisconsin
 2007 - Present Recruiting Director, Department of Pharmacology and Toxicology, Medical College of Wisconsin

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title: Estrogen Receptor, p38gamma MAPK and topo IIa in breast cancers
 Source: Merit Review
 Dates: 10/01/2007 - 09/01/2013
 Direct Funds: \$220,000

Title: Estrogen receptor, p38 MAPK and topo IIa in breast cancer
 Source: Merit Review
 Dates: 01/01/2009 - 12/01/2013

Direct Funds: \$150,000
Title: Estrogen receptor, p38 MAPK and topo
IIa in breast cancers
Source: Merit Review
Dates: 2009 - 2013
Direct Funds: \$150,000

Pending

Peer Review

Title: A MAPK and transcription factor axis in
Ras oncogenesis
Source: NIH R01
Title: Regulating breast cancer hormone
sensitivity by p38 MAPK
Source: Cancer Center (MCW)
Title: A MAPK and transcription factor axis in
Ras oncogenesis
Source: NIH
Title: Regulating breast cancer hormone
sensitivity by p38 MAPK
Source: MCW Cancer Center

Prior

Peer Review

Title: Inhibition of Ras mitogenic signaling by
the p38 pathway
Source: NIH
Dates: 01/01/2000 - 12/31/2005
Direct Funds: \$1,080,530
Title: Inhibition of Ras mitogenic signaling by
the p38 pathway
Source: NIH R01 (CA91576)
Dates: 2000 - 2005
Direct Funds: \$1,080,530
Title: Estrogen receptor regulates c-Jun
activity in breast cancer cells
Source: Merit Review Department of Veteran
Affairs
Dates: 01/01/2006 - 12/31/2009
Direct Funds: \$202,000
Title: Regulation of Ras activity by the p38
pathway
Source: NIH
Dates: 01/01/2006 - 12/31/2011
Direct Funds: \$155,000
Title: Estrogen receptor regulates c-Jun-
dependent cell death

Source: Charlotte Geyer Foundation
Dates: 01/01/2006 - 12/31/2007
Direct Funds: \$75,000

Title: VDR inhibits stress-induced cell death
Source: MCW Cancer Center
Dates: 01/01/2006 - 12/31/2007
Direct Funds: \$25,000

Title: Estrogen receptor regulates c-Jun-
dependent cell death
Source: Charlotte Geyer Foundation
Dates: 2006 - 2007
Direct Funds: \$75,000

Title: Regulation of Ras activity by the p38
pathway
Source: NIH R01
Dates: 2006 - 12/31/2011
Direct Funds: \$155,000

Title: VDR inhibits stress-induced cell death
Source: MCW Cancer Center
Dates: 2006 - 2007
Direct Funds: \$25,000

Title: Estrogen receptor regulates c-Jun
activity in breast cancer cells
Source: Merit Review Department of Veteran
Affairs
Dates: 2006 - 2009
Direct Funds: \$202,000

Title: Regulation of breast cancer invasion by
p38 MAPK
Source: MCW Cancer Center
Dates: 01/01/2008 - 12/31/2010

Title: Regulation of breast cancer invasion by
p38 MAPK
Source: MCW Cancer Center
Dates: 2008 - 2010

Title: Estrogen receptor and vitamin D
receptor cooperate in regulating breast
cancer invasion
Source: MCW Cancer Center
Dates: 01/01/2009 - 12/31/2011
Direct Funds: \$138,000

Title: Estrogen receptor and vitamin D
receptor cooperate in regulating breast
cancer invasion
Source: Cancer Center (MCW)
Dates: 2009 - 2011
Direct Funds: \$138,000

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

Symposium for Cancer Drug Resistance, Kiel, Germany, 1990
Annual German Cancer Research Meeting, Heidelberg, Germany, 1991
International Conference of Chemotherapy, Berlin, Germany, 1991
12th World Congress on Advances in Oncology, Crete, Greece, 2007
Symposium for Cancer Drug Resistance, Kiel, Germany, 1990
Annual German Cancer Research Meeting, Heidelberg, Germany, 1991
12th World Congress on Advances in Oncology, Crete, Greece, 2007
International Conference of Chemotherapy, Berlin, Germany, 1991

National

Isis Pharmaceutical, CA, 2000
Department of Pharmacology, George Washington University, Washington, DC, 2000
Tulane Cancer Center, Tulane University, New Orleans, LA, 2005
Department of Biochemistry, Virginia Commonwealth University (VCU), Richmond, Virginia, 2005
Department of Pediatrics and Cancer Center, University of Louisville, 2005
Molecular Biology, Mayo Clinic Arizona, Scottsdale, AZ, 2005
Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, 2005
Isis Pharmaceutical, CA, 2000
Department of Pharmacology, George Washington University, Washington, DC, 2000
Tulane Cancer Center, Tulane University, New Orleans, LA, 2005
Department of Biochemistry, Virginia Commonwealth University (VCU), Richmond, Virginia, 2005
Department of Pediatrics and Cancer Center, University of Louisville, 2005
Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, 2005
Molecular Biology, Mayo Clinic Arizona, Scottsdale, AZ, 2005

Regional

Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, 2000
Department of Radiation Oncology, Washington University in St. Louis, MO, 2000
Cancer Center, Loyola University Medical Center, Chicago, IL, 2000
Molecular Biology Program, Loyola University of Chicago, 2001
Program in Molecular and Cellular Biochemistry, Loyola University of Chicago, 2002
Department of Pharmacology and Experimental Therapeutics, Loyola University of Chicago, 2003
Program in Molecular Biology, Loyola University of Chicago, 2004
Department of Radiation Oncology, Loyola University of Chicago, 2005
Barbara Ann Karmanos Cancer Institute, Detroit, MI, 2006
Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, 2000
Department of Radiation Oncology, Washington University in St. Louis, MO, 2000
Cancer Center, Loyola University Medical Center, Chicago, IL, 2000
Molecular Biology Program, Loyola University of Chicago, 2001
Program in Molecular and Cellular Biochemistry, Loyola University of Chicago, 2002
Department of Pharmacology and Experimental Therapeutics, Loyola University of Chicago, 2003
Program in Molecular Biology, Loyola University of Chicago, 2004
Department of Radiation Oncology, Loyola University of Chicago, 2005
Barbara Ann Karmanos Cancer Institute, Detroit, MI, 2006

Local

Department of Biology, Toledo University, Toledo, OH, 2000
Medical College of Wisconsin, Department of Pharmacology, Milwaukee, WI, 2005
Department of Biology, Toledo University, Toledo, OH, 2000
Medical College of Wisconsin, Department of Pharmacology, Milwaukee, WI, 2005

MCW TEACHING ACTIVITIES:

Medical Student Education

01/01/2007 - 05/01/2007 Present Medical Pharmacology (Small group)

2007 - Present Medical Pharmacology (Small group)
01/01/2008 - 05/01/2008 Present Pharmacology, Herbs and Supplemental Medicine (lecture)
2008 - Present Pharmacology, Herbs and Supplemental Medicine (lecture)

Graduate Student Education

01/01/2006 - 12/31/2011 Present Nuclear Receptors-Mechanisms of Cellular Signaling (Course #16250) and the Course Director (2011)
2006 - Present Nuclear Receptors-Mechanisms of Cellular Signaling (Course #16250) and the Course Director (2011)
01/01/2008 - 12/31/2012 Present MAPKs and PI3Ks-Cellular Signal Transduction/ (Course #07224)
01/01/2008 - 12/31/2012 Present Analytic Methods in Pharmacology and Toxicology-Protein-protein interaction (Course #07243)
2008 - Present MAPKs and PI3Ks-Cellular Signal Transduction/ (Course #07224)
2008 - Present Analytic Methods in Pharmacology and Toxicology-Protein-protein interaction (Course #07243)
01/01/2010 - 12/31/2012 Present Cancer Genetics-Ras/MAPK signaling in cancer (Course #05251)
2010 - Present Cancer Genetics-Ras/MAPK signaling in cancer (Course #05251)

EXTRAMURAL TEACHING:

Medical Student Education

01/01/2001 - 10/31/2012 Present Department of Radiation Oncology, Loyola University of Chicago, Signal transduction, Genomic Instability
2001 - Present Department of Radiation Oncology, Loyola University of Chicago, Signal transduction, Genomic Instability
01/01/2002 - 12/31/2002 Department of Radiation Oncology, Loyola University of Chicago, MAPK and DNA repair, MAPK and Radiation response
2002 Department of Radiation Oncology, Loyola University of Chicago, MAPK and DNA repair, MAPK and Radiation response
01/01/2004 - 12/31/2005 Department of Radiation Oncology, Loyola University of Chicago, 1) Apoptosis & Radiation 2) Cell Kinetics (Radiobiology Basis)
2004 - 2005 Department of Radiation Oncology, Loyola University of Chicago, 1) Apoptosis & Radiation 2) Cell Kinetics (Radiobiology Basis)

Graduate Student Education

01/2001 - 12/2001 Loyola University of Chicago, Signal transduction Special Core Curriculum (#MIIM502817)
01/2001 - 05/2003 Loyola University of Chicago, Oncogenesis Molecular Biology Program (#MB10590)
01/2001 - 05/2002 Present Loyola University of Chicago, MAPK signaling Physiology (#471), Molecular Biology (#527), CBNA (#441)
2001 - Present Loyola University of Chicago, MAPK signaling Physiology (#471), Molecular Biology (#527), CBNA (#441)
2001 - 2003 Loyola University of Chicago, Oncogenesis Molecular Biology Program (#MB10590)
2001 Loyola University of Chicago, Signal transduction Special Core Curriculum (#MIIM502817)
01/2002 - 05/2003 Loyola University of Chicago, DNA repair Molecular Biology (#526)
2002 Loyola University of Chicago, DNA repair Molecular Biology (#526)
01/2005 - 05/2004 Present Loyola University of Chicago, Nuclear receptors Pharmacology (#409)
2005 - Present Loyola University of Chicago, Nuclear receptors Pharmacology (#409)

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:

Graduate Students

PhD Students Advised

2001 - 2003 Rocky Pramanik, Science Research, Co Scientist, Medical College of Wisconsin
2002 Zan Huang, Molecular Biology Rotating, Medical College of Wisconsin
2003 Viral Brahmhatt, CBNA/Biochemistry Rotating, Medical College of Wisconsin
2003 - 2005 Jun Tang, University of Chicago Research Asso, Medical College of Wisconsin

2004 Sreevidya Sivaswamy, Biochemistry Rotating, Medical College of Wisconsin
2005 - Present Mathew Loesch, Pharmacology Mentor, Medical College of Wisconsin
2007 Amy Sasman, Pharmacology Rotating, Medical College of Wisconsin
2007 Elizabeth Ntantie, IDP/Graduate School Rotating, Medical College of Wisconsin
2008 Dusanka Vesic, IDP/Graduate School Rotating, Medical College of Wisconsin
2008 Nicole Pohl, Pharmacology/MCW Mentor, Medical College of Wisconsin
2008 Kristin Aicher, IDP/Graduate School Rotating, Medical College of Wisconsin
2008 Adrinne Lepp, IDP/Graduate School Rotating, Medical College of Wisconsin
2008 Justin Reitsman, IDP/Graduate School Rotating, Medical College of Wisconsin
2009 Brandon-Rindfleisch, IDP/Graduate School Rotating, Medical College of Wisconsin
2009 Mathew Loesch, Pharmacology/MCW Mentor, Medical College of Wisconsin
2010 Yusuke Kobayashi, Yokohama City Co-Mentor University, Japan, Medical College of Wisconsin
2010 Mansi Karkhanis, IDP/Graduate School Rotating, Medical College of Wisconsin
Yalin Li, MCW Postdoc fellow, Medical College of Wisconsin
Songwang Hou, MCW Postdoc associate, Medical College of Wisconsin
Huiying Zhi, MCW Postdoc fellow, Medical College of Wisconsin

MA Students Advised

2002 - Present Zan Huang, Molecular Biology Rotating, MCW
2003 - 2005 Jun Tang, University of Chicago Research Asso, MCW
2003 - Present Viral Brahmabhatt, CBNA/Biochemistry Rotating, MCW
2004 - Present Sreevidya Sivaswamy, Biochemistry Rotating, MCW
2007 - Present Elizabeth Ntantie, IDP/Graduate School Rotating, MCW
2008 - Present Kristin Aicher, IDP/Graduate School Rotating, MCW
2008 - Present Adrinne Lepp, IDP/Graduate School Rotating, MCW
2008 - Present Dusanka Vesic, IDP/Graduate School Rotating, MCW
2009 - Present Brandon-Rindfleisch, IDP/Graduate School Rotating, MCW
Huiying Zhi, Postdoc fellow, MCW
Songwang Hou, Postdoc associate, MCW
Yalin Li, Postdoc fellow, MCW

MS Students Advised

2002 - 2003 Stanley J. Borowicz, CBNA/Biochemistry Co-Mentor, Medical College of Wisconsin
2003 Stanley J. Borowicz, CBNA/Biochemistry Co-Mentor Loyola, Medical College of Wisconsin
2004 - Present Nicole Pohl, Molecular Biology Mentor, Medical College of Wisconsin
2004 Melanie Weytkow, Pharmacology Summer, Medical College of Wisconsin
2005 Amrita Dhupelia, Pharmacology Summer, Medical College of Wisconsin
2011 Adrienne Lepp, Pharmacology/MCW Mentor, Medical College of Wisconsin
Adrienne Lepp, MCW Student, Medical College of Wisconsin
Xiaomei Qi, Medical College of Wisconsin

PhD Committees

2002 - 2005 Haixi Miao, Supervisor, Lucio Miller, Medical College of Wisconsin
2004 - 2005 Qinqing Li, Nanjing Medical Professor in China, Medical College of Wisconsin
2004 - 2009 Nicole Pohl, Supervisor, Dr. Guan Chen, Medical College of Wisconsin
2004 - 2005 Qinqing Li, Nanjing Medical Professor in China, Medical College of Wisconsin
2005 - 2009 Mathew Loesch, Supervisor, Dr. Guan Chen, Medical College of Wisconsin
2008 - 2010 Tracy Berg, Supervisor, Carol William (Pharmacology), Medical College of Wisconsin
2008 - 2009 Hong Guan, Supervisor, Robert Descheins, Biochemistry, Medical College of Wisconsin
2009 Nathan Schuld, IDP/Graduate School Rotating, Medical College of Wisconsin

MS Committees

2003 - 2005 Stanley Borowicz, Mater, Supervisor, Dr. Guan Chen, Medical College of Wisconsin
2009 - Present Adam Gastonguy, (Pharmacology), Supervisor, Carol William, Medical College of Wisconsin
2009 - Present Jaclyn Porath, (Blood Research Inst), Gil White, Medical College of Wisconsin
2010 - Present Adrienne Lepp, (Pharmacology), Supervisor, Guan Chen, Medical College of Wisconsin
2010 Benjamin Tourdot, (Blood Research Inst), Debra Newman, Medical College of Wisconsin
2010 Anna Alexanian, (Microbiology), Supervisor, Andrey Sorokin, Medical College of Wisconsin
2011 - Present Elizabeth Ntantie, (Pharmacology), Supervisor, Carol William, Medical College of Wisconsin

MA Committees

2009 - Present Nathan Schuld, IDP/Graduate School Rotating, Medical College of Wisconsin

MPh Students Advised

2010 Jessica Wilson, Medical School Rotating, Medical College of Wisconsin

Postdoctoral Researchers

2000 - 2001 Jin-Tang Wang, Canada Postdoc, Medical College of Wisconsin

2001 - 2002 Zan Huang, University of Chicago Postdoc, Medical College of Wisconsin

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS

MENTORED:

Graduate Students

PhD Committees

2000 - 2006 Haixi Miao, candidate for Biochemistry and Cell Biology Program, (Advisor: Lucia Miller), Loyola University of Chicago

01/2001 - 06/2003 Student Name 3, Dissertation title, UW-Milwaukee

2002 - 2004 Anisha Dcosta, candidate for Molecular Biology Program (Advisor: Mitch Denning), Loyola University of Chicago

2004 - Present Charles Gunawan, candidate for Pharmacology (Advisor: Tarun B. Patel)

2004 Vigneshwaran Krishnamoorthy, candidate for Department of Cellular and Molecular Physiology (Advisor: Jody L. Martin), Loyola University of Chicago

2005 Matew Loesch, candidate for Department of Pharmacology (Advisor: Guan Chen), Loyola University of Chicago

2005 Rakesh Singh, candidate for Department of Pharmacology (Advisor: Tarun Patel), Loyola University of Chicago

2005 Anita Jerome, candidate for Molecular Biology Program (Advisor: Mitch Denning), Loyola University of Chicago

2005 Nicole Phol, candidate for Molecular Biology Program (Advisor: Guan Chen), Loyola University of Chicago

MS Committees

2001 - 2003 Stanley Borowicz, a Master candidate for CBNA (Advisors: Guan Chen & Richard Schultz), Loyola University of Chicago

2003 - Present Yuanbin Chen, candidate for Molecular Biology Program (Advisor: Yan Su), Loyola University of Chicago

2006 Vigneshwaran Krishnamoorthy, Program in Cellular and Molecular Physiology, Loyola University of Chicago

MA Committees

GRANT REVIEW/STUDY SECTION:

01/01/2001 - 12/31/2001 Ohio Cancer Association, Florida Cancer Association

01/01/2001 - 12/31/2001 Present Ohio Cancer Association, Florida Cancer Association

01/01/2006 - 12/31/2006 Ad hoc scientific reviewer for DOD, Breast Cancer Research Program (CET-4, Clinical & Experimental Therapeutics #4 panel)

01/01/2006 - 10/12/2012 Cancer Center, Medical College of Wisconsin (MCW)

01/01/2007 - 12/31/2007 Ad hoc scientific reviewer for NIH MONC study section (Molecular Oncogenesis), ARRA RC1 Challenge Grant (ZRG1 OTC-K 58)

01/01/2007 - 10/12/2012 Ad hoc scientific reviewer for Special Research Program (SFB, Cell Proliferation and Cell Death in Tumors), Austrian Science Foundation (FWF), The Wellcome- Trust Foundation, England; Health Research Board, Ireland

01/01/2008 - 12/31/2008 Ad hoc scientific reviewer for Susan G. Komen for the Cure (TT-1, Target Therapeutics)

01/01/2008 - 10/12/2012 VA, Ad hoc Scientific reviewer for Oncology Study Section and Career

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Hou, S., Padmanaban, S., Qi, X., Lepp, A., Mirza, S. P., and Chen, G. p38gamma MAPK signals through phosphorylating its phosphatase PTPH1 in regulating Ras oncogenesis and stress response. *J Biol Chem* 2012,287: 27895-27950
2. Yusuke, Kobayashi, Xiaomei Qi, and Chen, G. MK2 regulates Ras oncogenesis through stimulating ROS production. *Gene & Cancer*, 2012 in press
3. Qi, X., Zhi, H., Lepp, A., Wang, P., Huang, J., Basir, Z., Chitambar, C. R., Myers, C. R., and Chen, G. p38gamma mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from the classical to the non-classical pathway via stimulating ER phosphorylation and c-Jun transcription. *J Biol Chem* 2012, 287: 14681-14691
4. Zhi HY, Hou SW, Li RS, Basir Z, Xiang Q, Szabo A, **Chen G**. PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization. *Oncogene*. 2011 Apr 07;30(14):1706-15. PMID: PMC3072445
5. Qi, X., Hou, S., Lepp, A., Li, R., Basir, Z., Lou, Z., and Chen, G. Phosphorylation and stabilization of topoisomerase II by p38 MAPK sensitize breast cancer cells to its poisons. *J Biol Chem* 2011, 286: 35883-35890
6. Zhi, H., Hou, S., Li, R., Basir, Z., Xiang, Q., Szabo, A., Chen, G. PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization. *Oncogene*, in press 2011, (this paper was highlighted by TIS, known as the Target Intelligence Service.)
https://www.targetintelligenceservice.com/main/public/case.jsp?report_id=43816
7. Hou, S., Lepp, A., Chen, G. (2010) p38gamma MAP kinase (review). UCSD-Nature Molecular Pages 1September 2010 / doi:10.1038/mp.a001720.01
8. Hou, S., Zhi, H., Pohl, N., Loesch, M., Qi, X., Li, R., Basir, Z., and Chen, G. (2010) PTPH1 dephosphorylates and cooperate with p38gamma MAPK to increase Ras oncogenesis through PDZ-mediated interaction. *Cancer Res.* 70: 2901-2910
9. Hou SW, Zhi HY, Pohl N, Loesch M, Qi XM, Li RS, Basir Z, **Chen G**. PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction. *Cancer Res.* 2010 Apr 01;70(7):2901-10. PMID: PMC2848905
10. Loesch, M., Zhi, H., Hou, S., Qi, X., Li, R., Basir, Z., Iftner, T., Cuenda, A., and Chen, G. (2010) p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. 2010, *J. Biol. Chem.* 285: 15149-15158
11. Loesch, M., Chen, G. The p38gamma MAPK stress pathway as a tumor suppressor or more? *Front. Biosci.*, 2008, 13: 3581-3593 (review).
12. Li QP, Qi X, Pramanik R, Pohl NM, Loesch M, **Chen G**. Stress-induced c-Jun-dependent Vitamin D receptor (VDR) activation dissects the non-classical VDR pathway from the classical VDR activity. *J Biol Chem.* 2007 Jan 19;282(3):1544-51.
13. Qi X, Pohl NM, Loesch M, Hou S, Li R, Qin JZ, Cuenda A, **Chen G**. p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response. *J Biol Chem.* 2007 Oct 26;282(43):31398-408.
14. Qi X, Tang J, Loesch M, Pohl N, Alkan S, **Chen G**. p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion. *Cancer Res.* 2006 Aug 01;66(15):7540-7. PMID: PMC2174269
15. Hou S, Suresh PS, Qi X, Lepp A, Mirza SP, **Chen G**. p38? Mitogen-activated protein kinase signals through phosphorylating its phosphatase PTPH1 in regulating ras protein oncogenesis and stress response. *J Biol Chem.* 2012 Aug 10;287(33):27895-905. PMID: PMC3431700
16. Hou S, Suresh PS, Qi X, Lepp A, Mirza SP, **Chen G**. p38? Mitogen-activated protein kinase signals through phosphorylating its phosphatase PTPH1 in regulating ras protein oncogenesis and stress response. *J Biol Chem.* 2012 Aug 10;287(33):27895-905. PMID: PMC3431700
17. Qi X, Zhi H, Lepp A, Wang P, Huang J, Basir Z, Chitambar CR, Myers CR, **Chen G**. p38? mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription. *J Biol Chem.* 2012 Apr 27;287(18):14681-91. PMID: PMC3340246
18. Zhi HY, Hou SW, Li RS, Basir Z, Xiang Q, Szabo A, **Chen G**. PTPH1 cooperates with vitamin D receptor to

- stimulate breast cancer growth through their mutual stabilization. *Oncogene*. 2011 Apr 07;30(14):1706-15. PMID: PMC3072445
19. Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, Iftner T, Cuenda A, **Chen G**. p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. *J Biol Chem*. 2010 May 14;285(20):15149-15158. PMID: PMC2865276
 20. Hou SW, Zhi HY, Pohl N, Loesch M, Qi XM, Li RS, Basir Z, **Chen G**. PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction. *Cancer Res*. 2010 Apr 01;70(7):2901-10. PMID: PMC2848905
 21. Qi XM, Wang F, Mortensen M, Wertz R, **Chen G**. Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy. *Acta Pharm Sin B*. 2018 Jul;8(4):511-517. PMID: PMC6089844
 22. Yin N, Lepp A, Ji Y, Mortensen M, Hou S, Qi XM, Myers CR, **Chen G**. The K-Ras effector p38? MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating *EGFR* transcription and EGFR dephosphorylation. *J Biol Chem*. 2017 Sep 08;292(36):15070-15079. PMID: PMC5592682
 23. **Chen G**, Templeton D, Suttle DP, Stacey DW. Ras stimulates DNA topoisomerase II alpha through MEK: a link between oncogenic signaling and a therapeutic target. *Oncogene*. 1999 Nov 25;18(50):7149-60.
 24. **Chen G**, Teicher BA, Frei E 3rd. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype. *Cancer Biochem Biophys*. 1998 Jun;16(1-2):139-55.
 25. **Chen G**, Shu J, Stacey DW. Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide. *Oncogene*. 1997 Oct 02;15(14):1643-51.
 26. **Chen G**, Teicher BA, Frei E 3rd. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthracycline CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. *Anticancer Res*. 1996;16(6B):3499-505.
 27. **Chen G**, Hutter KJ, Zeller WJ. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. *Cell Biol Toxicol*. 1995 Oct;11(5):273-81.
 28. **Chen G**, Waxman DJ. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. *Biochem Pharmacol*. 1995 May 26;49(11):1691-701.
 29. **Chen G**, Waxman DJ. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. *Biochem Pharmacol*. 1994 Mar 15;47(6):1079-87.
 30. **Chen G**, Ramachandran C, Krishan A. Thaliblastine, a plant alkaloid, circumvents multidrug resistance by direct binding to P-glycoprotein. *Cancer Res*. 1993 Jun 01;53(11):2544-7.
 31. **Chen G**, Zeller WJ. Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo. *Cancer Chemother Pharmacol*. 1993;33(2):157-62.
 32. **Chen G**, Zeller WJ. Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines. *Cancer Lett*. 1992 Oct 30;67(1):27-33.
 33. **Chen G**, Zeller WJ. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells. *Anticancer Res*. 1994;14(4A):1461-7.
 34. Bürkle A, **Chen G**, Küpper JH, Grube K, Zeller WJ. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. *Carcinogenesis*. 1993 Apr;14(4):559-61.
 35. **Chen G**, Todorov DK, Zeller WJ. Antitumor activity of thaliblastine (NSC-68075) in experimental ovarian tumor cell lines sensitive and resistant to cisplatin. *Cancer Lett*. 1992 Feb 29;62(2):173-7.
 36. **Chen G**, Zeller WJ. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. *Anticancer Res*. 1991;11(6):2231-7.
 37. Zeller WJ, Frühauf S, **Chen G**, Keppler BK, Frei E, Kaufmann M. Chemoresistance in rat ovarian tumours. *Eur J Cancer*. 1991;27(1):62-7.
 38. **Chen G**, Zeller WJ. Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo. *Cancer Chemother Pharmacol*. 1990;26(1):37-41.
 39. Zeller WJ, Frühauf S, **Chen G**, Eisenbrand G, Lijinsky W. Biological activity of hydroxylated chloroethylnitrosoureas. *Cancer Res*. 1989 Jun 15;49(12):3267-70.
 40. **Chen G**, Li W. Editorial Preface for Targeted Cancer Therapy *Acta Pharmaceutica Sinica B*. July 2018;8(4):501-502.
 41. Stacey DW, Hitomi M, **Chen G**. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity. *Mol Cell Biol*. 2000 Dec;20(24):9127-37. PMID: PMC102171

42. **Chen G**, Baechle A, Nevins TD, Oh S, Harmon C, Stacey DW. Protection against cyclophosphamide-induced alopecia and inhibition of mammary tumor growth by topical 1,25-dihydroxyvitamin D3 in mice. *Int J Cancer*. 1998 Jan 19;75(2):303-9.
43. Teicher BA, Holden SA, Ara G, **Chen G**. Transforming growth factor-beta in in vivo resistance. *Cancer Chemother Pharmacol*. 1996;37(6):601-9.
44. **Chen G**, Zeller WJ, Todorov DK. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin. *Anticancer Res*. 1993;13(5A):1269-75.
45. **Chen G**, Zeller WJ. Investigations on synergistic effects of BSO and 3AB for the reversal of cisplatin resistance *Tumor Diagnostik und Therapie*. 1991;12(6):226-229.
46. **Chen G**, Hutter KJ, Bullerdiek J, Zeller WJ. Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line. *J Cancer Res Clin Oncol*. 1991;117(6):539-42. PMID: PMC12201834
47. **Chen G**, Zeller WJ. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line. *J Cancer Res Clin Oncol*. 1990;116(5):443-7. PMID: PMC12201276
48. **Chen G**, Frei E, Zeller WJ. Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines. *Cancer Lett*. 1989 Aug;46(3):207-11.
49. **Chen G**, Hitomi M. Dissociation of CDK2 from cyclin A in response to the topoisomerase II inhibitor etoposide in v-src-transformed but not normal NIH 3T3 cells. *Exp Cell Res*. 1999 Jun 15;249(2):327-36.
50. **Chen G**, Waxman DJ. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. *J Pharmacol Exp Ther*. 1995 Sep;274(3):1271-7.
51. **Chen G**, Pan QC. Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. *Cancer Chemother Pharmacol*. 1988;22(4):303-7.
52. **Chen G**, Oh S, Monia BP, Stacey DW. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. *J Biol Chem*. 1996 Nov 08;271(45):28259-65.
53. **Chen G**, Zeller WJ. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin. *Anticancer Res*. 1993;13(1):219-23.
54. Chang TK, **Chen G**, Waxman DJ. Modulation of thiotepea antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. *J Pharmacol Exp Ther*. 1995 Jul;274(1):270-5.
55. **Chen G**, Li W. Editorial Preface for Targeted Cancer Therapy. *Acta Pharm Sin B*. 2018 Jul;8(4):501-502. PMID: PMC6090083
56. Fang Wang, Xiao-Mei Qi, Ryan Wertz, Matthew Mortensen, Catherine Hagen, John Evans, Yuri Sheinin, Michael James, Pengyuan Liu, Susan Tsai, James Thomas, Alexander Mackinnon, Michael Dwinell, Charles R Myers, Ramon Bartrons, Liwu Fu, Guan Chen. p38gamma MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis *Cancer Research*. Wang F, Qi XM, Wertz R, et al. p38gamma MAPK is essential for aerobic glycolysis and pancreatic tumorigenesis [published online ahead of print, 2020 Jun 24]. *Cancer Res*. 2020;canre.
57. Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bartrons Bach R, Fu L, **Chen G**. p38? MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. *Cancer Res*. 2020 Aug 15;80(16):3251-3264. PMID: PMC9358694
58. **Chen G**, Pan QC. [Enhancement of the antitumor activity of bleomycin A5 by 3-aminobenzamide in vitro and in vivo]. *Yao Xue Xue Bao*. 1985 May;20(5):331-3.
59. Qin JZ, Xin H, Qi XM, **Chen G**. Isoform-specific and cell/tissue-dependent effects of p38 MAPKs in regulating inflammation and inflammation-associated oncogenesis. *Front Biosci (Landmark Ed)*. 2022 Jan 18;27(1):31.
60. Qi XM, **Chen G**. p38? MAPK Inflammatory and Metabolic Signaling in Physiology and Disease. *Cells*. 2023 Jun 21;12(13). PMID: PMC10341180
61. Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bach RB, Fu L, **Chen G**. Correction: p38? MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. *Cancer Res*. 2025 Feb 17;85(4):825.
62. Qi X, Wang F, Thomas L, Ma S, Palen K, Lu Y, Sheinin Y, Gershan J, Fu L, **Chen G**. Protein tyrosine

phosphatase PTPH1 potentiates receptor tyrosine kinase HER2 oncogenesis via a PDZ-coupled and phosphorylation-driven scaffold. *Am J Cancer Res.* 2024;14(12):5734-5751. PMID: PMC11711543